Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Ciprofloxacin Drives RSL3-Induced Ferroptosis via Mitochondr

    2026-07-17

    Ciprofloxacin Potentiates Ferroptosis Through Mitochondrial Zinc Accumulation: Mechanistic Insights and Experimental Implications

    Study Background and Research Question

    Ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, has emerged as a promising avenue for cancer therapy due to its distinct molecular mechanisms and potential to overcome resistance to traditional treatments. Recent research has focused on the modulation of ferroptosis through metabolic and signaling pathways, aiming to selectively induce death in malignant cells while sparing healthy tissue. Ciprofloxacin (CFX), a widely used fluoroquinolone antibiotic, is known primarily for inhibiting bacterial DNA replication, but past studies have also hinted at its anti-tumor activity, including the induction of apoptosis and suppression of tumor cell proliferation.

    The dual and context-dependent effects of CFX on ferroptosis—suppressing erastin-induced ferroptosis while potentially enhancing ferroptosis triggered by other agents—prompted further investigation. The central research question addressed by Hu Tang et al. (2025) is: How does CFX interact with RSL3, a GPX4 inhibitor and potent ferroptosis inducer, in the regulation of ferroptosis in cancer cells, and what are the underlying molecular mechanisms?

    Key Innovation from the Reference Study

    The core innovation of the reference study lies in its identification of CFX as a context-dependent modulator of ferroptosis. Specifically, the research shows that CFX, when combined with RSL3, significantly enhances ferroptotic cell death in cancer cells by promoting mitochondrial zinc (Zn2+) accumulation. This effect is mediated via the STING1–CAV2 signaling pathway—a novel mechanistic link between antibiotic-induced mitochondrial stress, zinc homeostasis disruption, and ferroptosis amplification. These findings extend our understanding of how antibiotics can influence regulated cell death pathways beyond their canonical antibacterial roles.

    Methods and Experimental Design Insights

    The study employed a multi-faceted experimental strategy to dissect the interaction between CFX and RSL3 in cell death regulation. Key components of the experimental design included:

    • Tumor cell lines were treated with low-dose CFX alone, RSL3 alone, or their combination to assess synergistic effects on ferroptosis induction.
    • Measurement of cell viability was conducted using ATP-based luminescence assays, which are highly sensitive to changes in metabolic activity and cell health.
    • Mitochondrial DNA stress and reactive oxygen species (ROS) production were quantified to establish mechanistic links between CFX action and mitochondrial dysfunction.
    • Intracellular and mitochondrial zinc levels were monitored using specific fluorescent probes and chelators.
    • Genetic and pharmacologic modulation of the STING1–CAV2 pathway and solute carrier family 25 member 25 (SLC25A25) was used to validate their roles in zinc transport and ferroptosis execution.
    • Comparative analysis with known ferroptosis inducers (e.g., erastin) and inhibitors (e.g., GPX4 stabilizers) provided context for CFX's dual function.

    The use of luciferase luminescence detection assays enabled rapid, quantitative, and reproducible readouts of cell viability, supporting high-throughput screening and mechanistic interrogation.

    Protocol Parameters

    • CFX concentration: Low-dose regimens (typically in the micromolar range); titrate to avoid off-target cytotoxicity.
    • RSL3 treatment: Administered at nanomolar to low micromolar concentrations for effective GPX4 inhibition and ferroptosis induction.
    • Cell viability measurement: ATP-based luminescent assays; optimal signal detected within 10–30 minutes post-reagent addition, consistent with product information.
    • Mitochondrial Zn2+ detection: Use of selective fluorescent probes, with pre-incubation periods tailored to ensure adequate mitochondrial uptake.
    • STING1–CAV2 pathway modulation: siRNA knockdown or pharmacological inhibitors applied according to validated protocols; typically 24–48 hours before co-treatment with CFX and RSL3.
    • ROS quantification: MitoSOX or similar mitochondrial superoxide indicators, applied 30–60 minutes prior to endpoint measurement.

    Core Findings and Why They Matter

    The study's main findings elucidate a previously unrecognized pro-ferroptotic function of CFX under specific experimental conditions:

    • CFX, while stabilizing GPX4 and suppressing erastin-induced ferroptosis in prior work, enhances RSL3-induced ferroptosis through a distinct mechanism.
    • Combined CFX and RSL3 treatment leads to pronounced mitochondrial DNA stress and ROS generation, exceeding the effects of either agent alone (reference study).
    • This stress activates the STING1–CAV2 pathway, resulting in increased mitochondrial import of Zn2+ via SLC25A25.
    • Elevated mitochondrial Zn2+ disrupts redox homeostasis, amplifying oxidative damage and ferroptotic cell death.

    These findings are significant because they redefine the role of CFX in cancer biology, suggesting that its impact on regulated cell death is highly context- and stimulus-dependent. The results also highlight mitochondrial zinc homeostasis as a modifiable determinant of ferroptosis sensitivity, with potential implications for the design of combinatorial cancer therapies that exploit this vulnerability.

    Comparison with Existing Internal Articles

    Several internal resources provide complementary perspectives on the mechanistic and methodological implications of these findings:

    Together, these resources emphasize the convergence of mechanistic research and assay technology, demonstrating that next-generation viability assays are essential for uncovering subtle, context-dependent effects in cell death research.

    Limitations and Transferability

    Despite its strengths, the reference study does have limitations that should be considered when interpreting or translating the findings:

    • The pro-ferroptotic effect of CFX was observed in specific cancer cell lines and under defined concentrations of CFX and RSL3; generalizability to other cell types or in vivo models remains to be established.
    • The reliance on ATP-based luminescence detection, while highly sensitive, primarily reflects metabolic viability rather than direct cell death endpoints, so complementary assays (e.g., lipid peroxidation or apoptosis assays) may be needed for full mechanistic validation.
    • While the STING1–CAV2 pathway and mitochondrial Zn2+ import were validated as mediators in this context, the broader landscape of zinc transporters and ferroptosis regulators warrants further exploration.

    These considerations underscore the importance of careful experimental design and the need for orthogonal validation approaches when extending these findings to other disease models or therapeutic settings.

    Research Support Resources

    Robust cell viability measurement is critical for mechanistic studies of regulated cell death and drug response. Researchers aiming to reproduce or extend the workflows described in this study can employ sensitive, rapid luminescence-based assays. The Luminescent ATP Cell Viability Assay Kit I (SKU: K2041) from APExBIO provides a validated solution for high-throughput ATP detection, leveraging firefly luciferase luminescence to quantify metabolically active cells with minimal workflow complexity. This platform is especially well-suited for cytotoxicity and metabolism studies where accurate, early detection of cell viability is essential for dissecting ferroptosis and its modulators.